NCT03236649 2023-02-08
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Beijing Shenogen Biomedical Co., Ltd
Phase 3 Terminated
Clinical Trials
29 trialsNCT03582618 2023-01-10
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Terminated
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT01141478 2021-10-15
HCC
Loma Linda University
Phase NA Terminated
NCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01887717 2021-04-21
YES-P
Boston Scientific Corporation
Phase 3 Terminated
NCT02460991 2021-02-12
SOLACE
Boston Scientific Corporation
Phase 3 Terminated
NCT00823290 2020-12-14
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
University of Erlangen-Nürnberg Medical School
Phase 1 Terminated
NCT03644511 2020-08-21
SORAGO-HCC
Bayer
Terminated
NCT02867280 2020-02-11
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Sun Yat-sen University
Phase 3 Terminated
NCT02748304 2019-02-15
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
Fudan University
Phase NA Terminated
NCT02220088 2019-01-11
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Sun Yat-sen University
Phase 2/3 Terminated
NCT01005875 2017-05-10
RAD 0901
University of Alabama at Birmingham
Phase NA Terminated
NCT01171482 2017-04-26
Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
Seoul National University Hospital
Phase 2 Terminated
NCT02323906 2017-03-20
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Celgene
Phase 1 Terminated
NCT00576056 2017-02-15
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
University of Pittsburgh
Phase 2 Terminated
NCT00971126 2016-05-04
Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 1/2 Terminated
NCT01480817 2016-04-29
Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
Seoul National University Hospital
Phase 2 Terminated
NCT01348503 2015-08-31
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
Indiana University
Phase 1 Terminated
NCT01029418 2015-04-16
AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
National Cancer Centre, Singapore
Phase 1/2 Terminated
NCT00862082 2013-08-23
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Proacta, Incorporated
Phase 1/2 Terminated
NCT00828594 2013-04-11
Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 1 Terminated
NCT00699374 2013-01-14
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Pfizer
Phase 3 Terminated
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated
NCT00618384 2012-06-07
SOCRATES
Heinrich-Heine University, Duesseldorf
Phase 2 Terminated
NCT00767468 2012-05-23
Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT01337492 2012-03-21
Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT00873002 2012-03-20
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00791544 2010-08-04
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
Sanofi
Phase 1/2 Terminated